Core Points - BioPorto A/S has completed a private placement of 40,438,426 new shares, raising approximately DKK 43 million in new capital [1][2] - The new shares represent 8.89% of BioPorto's registered share capital prior to the increase [2] - The nominal share capital of BioPorto now amounts to DKK 495,108,887, consisting of 495,108,887 shares [4] Company Overview - BioPorto is an in vitro diagnostics company focused on improving patient outcomes through actionable kidney biomarkers, particularly for Acute Kidney Injury (AKI) [5] - The company's flagship products utilize the NGAL biomarker to aid in the risk assessment and management of AKI, enabling earlier intervention [5] - BioPorto's tests are marketed under various registrations, including CE mark in several countries and FDA clearance for ProNephro AKI™ in the US [5] Trading and Listing - The new shares will be admitted to trading and officially listed on Nasdaq Copenhagen A/S under the company's permanent ISIN code [3] - The new shares carry the same rights as existing shares, including the right to receive dividends from the time the capital increase is registered [3] Capital Structure - Following the capital increase, BioPorto's Articles of Association have been updated to reflect the new share capital structure [4] - The company emphasizes its commitment to transparency and provides access to its announcements and relevant information through its investor relations platform [4]

Company Overview - QuidelOrtho Corporation is a global leader in in vitro diagnostics, focusing on innovative diagnostic technologies for point-of-care settings, clinical labs, and transfusion medicine [1][3] - The company specializes in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, providing fast, accurate, and reliable diagnostics [4] Upcoming Event - QuidelOrtho's management team will participate in the Baird 2025 Global Healthcare Conference on September 10, 2025, with a fireside chat scheduled to begin at 3:10 p.m. ET / 12:10 p.m. PT [1] Access to Information - Interested parties can access the live webcast and replay of the event through the "Events & Presentations" section on QuidelOrtho's Investor Relations page [2]

Core Insights - QuidelOrtho aims to enhance diagnostic excellence by repurposing and certifying high-performing analyzers to improve access to reliable diagnostic technology for healthcare facilities in underserved communities [1][3] - The certification process for analyzers includes over 140 system checks, functional adjustments, hardware cleaning or replacement, and extensive performance testing, ensuring alignment with QuidelOrtho's quality and performance criteria [1][2] - The program features certified VITROS XT 7600 and 5600 Integrated Systems and the VITROS 3600 Immunodiagnostic System, designed to support community labs with general chemistries, immunoassay tests, and drug screening [2] Company Overview - QuidelOrtho Corporation (Nasdaq: QDEL) is a leader in in vitro diagnostics, focusing on developing intelligent solutions that transform data into actionable insights for a broader audience [4] - The company specializes in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, providing fast, accurate, and reliable diagnostics across various settings [4][5] - QuidelOrtho is committed to advancing diagnostics and improving healthcare outcomes through innovation and collaboration with global healthcare customers [5]

Core Viewpoint - QuidelOrtho Corporation will report its financial results for the second quarter of 2025 on August 5, 2025, after market close [1] Financial Results Announcement - The financial results will be discussed in a conference call scheduled for 2:00 p.m. PT / 5:00 p.m. ET on the same day [2] - Interested parties can access the call via the Company's Investor Relations page or by phone using specific dial-in numbers [2] Replay Availability - A replay of the conference call will be available shortly after the event on the Company's Investor Relations page [3] Company Overview - QuidelOrtho Corporation is a leader in in vitro diagnostics, focusing on innovative solutions that enhance understanding and action in healthcare [4] - The company specializes in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, providing reliable diagnostics across various settings [4][5]